DE60216281D1 - Die verwendung von tyrosinkinasehemmer zur behandlung von allergischen erkrankungen - Google Patents

Die verwendung von tyrosinkinasehemmer zur behandlung von allergischen erkrankungen

Info

Publication number
DE60216281D1
DE60216281D1 DE60216281T DE60216281T DE60216281D1 DE 60216281 D1 DE60216281 D1 DE 60216281D1 DE 60216281 T DE60216281 T DE 60216281T DE 60216281 T DE60216281 T DE 60216281T DE 60216281 D1 DE60216281 D1 DE 60216281D1
Authority
DE
Germany
Prior art keywords
treatment
tyrosine kinase
allergic diseases
kinase inhibitor
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60216281T
Other languages
English (en)
Other versions
DE60216281T2 (de
Inventor
Alain Moussy
Jean-Pierre Kinet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AB Science SA
Original Assignee
AB Science SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AB Science SA filed Critical AB Science SA
Application granted granted Critical
Publication of DE60216281D1 publication Critical patent/DE60216281D1/de
Publication of DE60216281T2 publication Critical patent/DE60216281T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60216281T 2001-06-29 2002-06-28 Die verwendung von tyrosinkinasehemmer zur behandlung von allergischen erkrankungen Expired - Lifetime DE60216281T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30140801P 2001-06-29 2001-06-29
US301408P 2001-06-29
PCT/IB2002/003297 WO2003002106A2 (en) 2001-06-29 2002-06-28 Use of tyrosine kinase inhibitions for treating allergic diseases

Publications (2)

Publication Number Publication Date
DE60216281D1 true DE60216281D1 (de) 2007-01-04
DE60216281T2 DE60216281T2 (de) 2007-07-05

Family

ID=23163215

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60216281T Expired - Lifetime DE60216281T2 (de) 2001-06-29 2002-06-28 Die verwendung von tyrosinkinasehemmer zur behandlung von allergischen erkrankungen

Country Status (11)

Country Link
US (1) US7700610B2 (de)
EP (1) EP1401413B1 (de)
JP (1) JP2004537536A (de)
AT (1) ATE345839T1 (de)
CA (1) CA2452371A1 (de)
CY (1) CY1106011T1 (de)
DE (1) DE60216281T2 (de)
DK (1) DK1401413T3 (de)
ES (1) ES2274993T3 (de)
PT (1) PT1401413E (de)
WO (1) WO2003002106A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2266553T3 (es) * 2001-06-29 2007-03-01 Ab Science Utilizacion de derivados de la n-fenil-2-pirimidina-amina para tratar las enfermedades inflamatorias.
ES2274075T3 (es) * 2001-06-29 2007-05-16 Ab Science Utilizacion de inhibidores de c-kit para tratar enfermedades inflamatorias intestinales (eii).
WO2003004006A2 (en) * 2001-06-29 2003-01-16 Ab Science Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
ATE401079T1 (de) * 2001-06-29 2008-08-15 Ab Science Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen
EP1401413B1 (de) 2001-06-29 2006-11-22 AB Science Die verwendung von tyrosinkinasehemmer zur behandlung von allergischen erkrankungen
DE60223063T2 (de) * 2001-06-29 2008-07-17 Ab Science C-kit inhibitoren
ATE404202T1 (de) * 2001-09-20 2008-08-15 Ab Science Die verwendung von potenten, selektiven und nontoxischen c-kithemmern zur behandlung von interstitieller blasenentzündung
US20040242612A1 (en) * 2001-09-20 2004-12-02 Alain Moussy Use of tyrosine kinase inhibitors for promoting hair growth
WO2003072090A2 (en) * 2002-02-27 2003-09-04 Ab Science Use of tyrosine kinase inhibitors for treating cns disorders
US20060052387A1 (en) * 2002-06-26 2006-03-09 Marsh Clay B Organic compounds
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
EP1525200B1 (de) 2002-08-02 2007-10-10 AB Science 2-(3-aminoaryl)amino-4-aryl-thiazole und ihre verwendung als c-kit inhibitoren
CN1950347B (zh) 2003-10-23 2012-04-04 Ab科学公司 作为酪氨酸激酶抑制剂的2-氨基芳基噁唑化合物
WO2005115385A1 (en) * 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating acne
KR20080019578A (ko) 2005-04-04 2008-03-04 에이비 사이언스 치환된 옥사졸 유도체 및 이의 티로신 키나제 억제제로서의용도
CN101657446B (zh) 2007-02-13 2013-05-15 Ab科学有限公司 合成作为激酶抑制剂的2-氨基噻唑化合物的方法
KR101924247B1 (ko) 2011-07-27 2019-02-22 에이비 사이언스 선택적 프로테인 키나제 저해제로서 옥사졸 및 티아졸 유도체
CA3172586A1 (en) 2013-07-31 2015-02-05 Avalyn Pharma Inc. Aerosol imatininb compounds and uses thereof

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558653A (en) 1968-05-20 1971-01-26 Searle & Co Dialkylaminoalkyl-indolines
US3725403A (en) 1970-10-20 1973-04-03 Squibb & Sons Inc Benzothiazine derivatives
US4438267A (en) * 1980-11-11 1984-03-20 Daluge Susan M Monoheteroring compounds and their use
GB8913708D0 (en) 1989-06-14 1989-08-02 Unilever Plc Cosmetic composition
US5308839A (en) 1989-12-04 1994-05-03 The Research Foundation Of State University Of New York Composition comprising non-steroidal anti-inflammatory agent tenidap and effectively non-antibacterial tetracycline
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (de) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5639757A (en) * 1995-05-23 1997-06-17 Pfizer Inc. 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
EP0902791A4 (de) * 1996-04-10 2002-10-16 Human Genome Sciences Inc Extrazellulärer/epidermaler wachstumsfaktor hcaba58x
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
JP2001512309A (ja) 1997-02-11 2001-08-21 メルク エンド カンパニー インコーポレーテッド プロテインチロシンキナーゼ２の阻害物質の同定
WO1998041525A1 (en) 1997-03-19 1998-09-24 Basf Aktiengesellschaft Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors
CA2289102A1 (en) 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
WO1998055152A1 (en) 1997-06-06 1998-12-10 Baylor College Of Medicine The mast cell secretory machine as a target for anti-allergy drug development
US6114371A (en) 1997-06-20 2000-09-05 Sugen, Inc. 3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
DE69807085D1 (de) 1997-09-02 2002-09-12 Bristol Myers Squibb Pharma Co Heterocyclyl-substituierte annellierte pyridine und pyrimidine als antagonisten des corticotropin freisetzenden hormons (crh), verwendbar für die behandlung von cns und stress
US6133305A (en) 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
US5952374A (en) 1997-09-29 1999-09-14 Protein Technologies International, Inc. Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
WO1999061028A1 (en) 1998-05-27 1999-12-02 Gorbach Sherwood L Isoflavonoids for treatment and prevention of migraine headaches
DK2020408T3 (da) 1998-05-29 2013-09-30 Sugen Inc Pyrrol-substitueret 2-indolinon som proteinkinaseinhibitor
DE19824922A1 (de) 1998-06-04 1999-12-09 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
CZ20004727A3 (cs) 1998-06-19 2002-03-13 Pfizer Products Inc. Deriváty pyrrolo[2,3-d] pyrimidinu
ATE371453T1 (de) 1998-08-13 2007-09-15 Novartis Pharma Gmbh Verfahren zur behandlung von okularen neovaskularen erkrankungen
DE19844003A1 (de) 1998-09-25 2000-03-30 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
WO2000040971A1 (en) 1998-12-31 2000-07-13 Sugen, Inc. Pyk2 (raftk) and inflammation
US6498176B1 (en) * 1999-03-04 2002-12-24 Smithklinebeecham Corporation 3-(anilinomethylene) oxindoles as protein tyrosine kinase and protein serine/threonine kinase inhibitors
US6245759B1 (en) * 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
CN1511830A (zh) 1999-03-12 2004-07-14 ���ָ��.Ӣ��ķҩ�﹫˾ 作为消炎剂的化合物
JP2002540096A (ja) 1999-03-24 2002-11-26 スージェン・インコーポレーテッド キナーゼ阻害剤としてのインドリノン化合物
US6989248B2 (en) 1999-05-06 2006-01-24 The Trustees Of Columbia University In The City Of New York Methods of use of compounds which inhibit the stem cell signaling pathway
CA2383546A1 (en) 1999-06-30 2001-01-04 William H. Parsons Src kinase inhibitor compounds
JP3952369B2 (ja) 1999-08-27 2007-08-01 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 新規な置換インドリノン類、その製造及びその薬剤としての使用
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
US6762180B1 (en) 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
DK1255536T3 (da) * 1999-12-22 2006-10-30 Sugen Inc Indolinonderivater til modulation af c-kit-tyrosinproteinkinase
ATE480558T1 (de) 1999-12-23 2010-09-15 Univ Geneve Auf scf peptid basiertes basolaterales sortiersignal und inhibitoren dafür
US6339100B1 (en) 1999-12-29 2002-01-15 The Trustees Of Columbia University In The City Of New York Methods for inhibiting mastocytosis
WO2001060816A1 (en) 2000-02-17 2001-08-23 Amgen Inc. Kinase inhibitors
US6420382B2 (en) * 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
US7105550B2 (en) 2000-03-01 2006-09-12 Christopher Love 2,4-disubstituted thiazolyl derivatives
US7087608B2 (en) 2000-03-03 2006-08-08 Robert Charles Atkins Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
CA2424470C (en) * 2000-10-27 2009-06-09 Novartis Ag Treatment of gastrointestinal stromal tumors
JP2004522713A (ja) 2000-11-17 2004-07-29 ブリストル−マイヤーズ　スクイブ　カンパニー ｐ３８キナーゼ関連疾患の処置方法およびキナーゼインヒビターとして有用なピロロトリアジン化合物
PE20020776A1 (es) 2000-12-20 2002-08-22 Sugen Inc Indolinonas 4-aril sustituidas
US6960580B2 (en) 2001-03-08 2005-11-01 Millennium Pharmaceuticals, Inc. Nitrogenous heterocyclic substituted quinoline compounds
GB0108606D0 (en) 2001-04-05 2001-05-23 Novartis Ag Organic compounds
EP1721609A3 (de) * 2001-05-16 2007-01-31 GPC Biotech AG Pyridylpyrimidinderivate als effektive Verbindungen gegen Prioninfektionen und prion Erkrankungen
US20030091974A1 (en) 2001-06-29 2003-05-15 Alain Moussy Method for screening compounds capable of depleting mast cells
DE60223063T2 (de) 2001-06-29 2008-07-17 Ab Science C-kit inhibitoren
WO2003002107A2 (en) 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating multiple sclerosis (ms)
EP1401413B1 (de) 2001-06-29 2006-11-22 AB Science Die verwendung von tyrosinkinasehemmer zur behandlung von allergischen erkrankungen
WO2003002114A2 (en) 2001-06-29 2003-01-09 Ab Science Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis
ATE401079T1 (de) 2001-06-29 2008-08-15 Ab Science Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen
WO2003004006A2 (en) 2001-06-29 2003-01-16 Ab Science Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
ES2274075T3 (es) 2001-06-29 2007-05-16 Ab Science Utilizacion de inhibidores de c-kit para tratar enfermedades inflamatorias intestinales (eii).
ES2266553T3 (es) 2001-06-29 2007-03-01 Ab Science Utilizacion de derivados de la n-fenil-2-pirimidina-amina para tratar las enfermedades inflamatorias.
US20040266771A1 (en) 2001-06-29 2004-12-30 Alain Moussy Use of tyrosine kinase inhibitors for treating bone loss
EP2277991A1 (de) * 2001-08-21 2011-01-26 Ventana Medical Systems, Inc. Verfahren und Quantifizierungstest zur Bestimmung des c-Kit-/SCF-/pAkt-Status
ATE404202T1 (de) 2001-09-20 2008-08-15 Ab Science Die verwendung von potenten, selektiven und nontoxischen c-kithemmern zur behandlung von interstitieller blasenentzündung
US20040242612A1 (en) 2001-09-20 2004-12-02 Alain Moussy Use of tyrosine kinase inhibitors for promoting hair growth
WO2003039550A1 (en) 2001-09-20 2003-05-15 Ab Science Use of tyrosine kinase inhibitors for whitening human skin and treating melanocyte dysfunction associated diseases
WO2003035049A2 (en) 2001-09-20 2003-05-01 Ab Science Use of potent, selective and non-toxic c-kit inhibitors for treating bacterial infections
IL162838A0 (en) 2002-01-04 2005-11-20 Univ Rockefeller Compositions and methods for prevention and treatment peptide-of amyloid- related disorders
EP1467981A1 (de) 2002-01-25 2004-10-20 Kylix Pharmaceuticals B.V. 4-(hetero)aryl-substituierte (thia-/oxa-/pyra)zole zur inhibierung von tie-2
WO2003072090A2 (en) 2002-02-27 2003-09-04 Ab Science Use of tyrosine kinase inhibitors for treating cns disorders
US20050089838A1 (en) 2002-06-28 2005-04-28 Alain Moussy Method for identifying compounds that specifically deplete mast cells
EP1525200B1 (de) 2002-08-02 2007-10-10 AB Science 2-(3-aminoaryl)amino-4-aryl-thiazole und ihre verwendung als c-kit inhibitoren
US20060275769A1 (en) 2003-01-06 2006-12-07 Oregon Health & Science University Methods of treatment and diagnosis of kaposi's sarcoma (ks) and ks related diseases

Also Published As

Publication number Publication date
CA2452371A1 (en) 2003-01-09
WO2003002106A3 (en) 2003-05-30
JP2004537536A (ja) 2004-12-16
EP1401413A2 (de) 2004-03-31
EP1401413B1 (de) 2006-11-22
US20040259893A1 (en) 2004-12-23
PT1401413E (pt) 2007-02-28
DE60216281T2 (de) 2007-07-05
DK1401413T3 (da) 2007-03-26
CY1106011T1 (el) 2011-04-06
ATE345839T1 (de) 2006-12-15
US7700610B2 (en) 2010-04-20
WO2003002106A2 (en) 2003-01-09
ES2274993T3 (es) 2007-06-01

Similar Documents

Publication Publication Date Title
ATE404202T1 (de) Die verwendung von potenten, selektiven und nontoxischen c-kithemmern zur behandlung von interstitieller blasenentzündung
DE60216281D1 (de) Die verwendung von tyrosinkinasehemmer zur behandlung von allergischen erkrankungen
WO2003002114A3 (en) Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis
ATE330608T1 (de) Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen
ATE401079T1 (de) Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen
CY1105930T1 (el) Χρηση αναστολεων c-kit για θepαπεια ασθενειων φλεγμονωδους εντερου (ibd)
DE60225590D1 (de) C-kithemmer zur behandlung von bakteriellen infektionen
ATE395052T1 (de) Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes
WO2003002107A3 (en) Use of tyrosine kinase inhibitors for treating multiple sclerosis (ms)
DE60227701D1 (de) Die verwendung von c-kithemmern zur förderung des haarwuchses
ATE453707T1 (de) Verfahren zur isolierung von mesenchymalen stammzellen des haarfollikels
ATE334693T1 (de) Verwendung von tyrosine-kinase inhibitoren zur behandlung von cns krankheiten
WO2003002105A3 (en) Use of tyrosine kinase inhibitors for treating bone loss
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
ATE260653T1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
WO2003004006A8 (en) Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
DE69934096D1 (de) Zusammensetzungen und methoden zur wundheilung
ATE402699T1 (de) Verwendung von substituierten pyrazolen zur behandlung von allergien
DE60323613D1 (de) Verwendung von tyrosinkinase-hemmern zur behandlung von erkrankungen im zusammenhang mit substanzgebrauch
DE60027127D1 (de) Verwendung von Polyaminosäurederivaten zur Behandlung von Seborrhoe und verwandten Hautstörungen
DE60213450D1 (de) Chinolinderivate, herstellungsprozess und verwendung zur behandlung von krankheiten, bei den s-cd23 involviert ist
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition